-+ 0.00%
-+ 0.00%
-+ 0.00%

Sensei Biotherapeutics To Implement 1-For-20 Reverse Stock Split Of Issued And Outstanding Shares, Effective June 16, 2025

Benzinga·06/13/2025 11:31:43
Listen to the news

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on May 21, 2025, with the final ratio subsequently determined by the Company's Board of Directors. The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Tuesday, June 17, 2025 under the Company's existing trading symbol "SNSE" with the new CUSIP number 81728A207.